PMID- 33966411
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 4
DP  - 2021 Apr
TI  - Effectiveness and safety of aspirin combined with letrozole in the treatment of 
      polycystic ovary syndrome: a systematic review and meta-analysis.
PG  - 4632-4641
LID - 10.21037/apm-21-606 [doi]
AB  - BACKGROUND: Meta-analysis was used to evaluate the efficacy and safety of aspirin 
      combined with letrozole in the treatment of polycystic ovary syndrome (PCOS). 
      METHODS: Through comprehensive searches of the China Knowledge Network (CNKI), 
      the VIP database (VIP), the Wanfang database, the China Biomedical Database 
      (CBM), PubMed, EMBASE, and the Cochrane Library, the clinical randomized 
      controlled trials (RCTs) published on aspirin combined with letrozole in the 
      treatment of PCOS were collected. According to the inclusion and exclusion 
      criteria, the included studies were screened and quality evaluated, and RevMan 
      5.3 software was used for meta-analysis. RESULTS: A total of 10 RCTs and 948 
      patients with PCOS were included. Meta-analysis results showed that compared with 
      letrozole monotherapy, aspirin combined with letrozole could significantly 
      increase the thickness of the endometrium [MD=1.98, 95% CI: 1.63-2.34, 
      P<0.00001], cervical mucus scores (MD =1.65, 95% CI: 1.32-1.98, P<0.00001), the 
      ovulation rate (OR=3.50, 95% CI: 2.08-5.91, P<0.00001), the number of mature 
      follicles (MD=0.65, 95% CI: 0.51-0.78, P<0.00001), and the pregnancy rate 
      (OR=3.06, 95% CI: 2.28-4.12, P<0.00001), and significantly reduced the abortion 
      rate (OR=0.20, 95% CI: 0.11-0.38, P<0.00001). There was no statistically 
      significant difference in the incidence of adverse reactions between the 2 groups 
      (OR=0.76, 95% CI: 0.44-1.32, P=0.33). CONCLUSIONS: Aspirin combined with 
      letrozole in the treatment of PCOS is safe and effective. Due to the limitations 
      in the number and quality of the included studies, further verification with 
      multi-center, large-sample, high-quality RCTs is still needed.
FAU - Yu, Qinjian
AU  - Yu Q
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
FAU - Wang, Zhihui
AU  - Wang Z
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
FAU - Su, Fangfang
AU  - Su F
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
FAU - Wang, Mianmian
AU  - Wang M
AD  - Department of Obstetrics and Gynecology, The Dingli Clinical College of Wenzhou 
      Medical University, Wenzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 7LKK855W8I (Letrozole)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - China
MH  - Female
MH  - Humans
MH  - Letrozole/therapeutic use
MH  - Ovulation Induction
MH  - *Polycystic Ovary Syndrome/drug therapy
MH  - Pregnancy
OTO - NOTNLM
OT  - Aspirin
OT  - letrozole
OT  - meta-analysis
OT  - polycystic ovary syndrome (PCOS)
EDAT- 2021/05/11 06:00
MHDA- 2021/05/15 06:00
CRDT- 2021/05/10 05:29
PHST- 2021/02/05 00:00 [received]
PHST- 2021/04/17 00:00 [accepted]
PHST- 2021/05/10 05:29 [entrez]
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
AID - 10.21037/apm-21-606 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Apr;10(4):4632-4641. doi: 10.21037/apm-21-606.